Spiromann

Developing a lung health monitoring device

Location
Copenhagen, Denmark
Revenue size
0 (pre-revenue)
Year founded
2022
Funding raised
EUR 140.000
Founders
Neta Meitlis, Dan Avrahamson, Jesper Ellegard
Most relevant investors
Private business angel
Team size
5
Website

www.Spiromann.com

Problem

Every day hundreds of millions people worldwide suffer from asthma, and the painful, persistent symptoms and side effects that follow this chronic condition. The uncertainty that comes with having reduced lung capacity immobilizes the patient, and further causes daily stress, worry and suffering, both for themselves and their network of family, friends and caretakers.

SOLUTION

Spiromann has developed a pocket sized, personal device called The Intelligent Personal Portable Inflammometer (IPPI), that gives asthma patients back their independence and peace of mind, and thus improves their general quality of life. The IPPI provides the patient with an easy, accessible and affordable method, to continuously track and analyze lung function, no matter where or when the need arises. Simply put, the IPPI measures the fractional exhaled Nitrogen Oxide from a single breath, analyzes the exhaled gasses and provides the user with direct, instant comprehension of the real-time status of their lung health, presented in a connected app. Through the app, the user will further be able to keep a personal record, and stay informed on potential parameters of influence such as temperature and other environmental factors.

KEY CUSTOMERS AND INTERNATIONAL PRESENCE

The IPPI is designed to meet US and EU regulatory compliance standards for diagnostic support, and thus cater to multiple markets.

Team

The team behind Spiromann is a small, multidisciplinary and international unit, with the common ambition of alleviating asthma patients all over the world. The three co-founders come from diverse backgrounds within product development, innovation, biosensors and software development, altogether representing a highly-skilled and well-experienced team.

Unique selling point

Spiromann’s IPPI combines user-centric accessibility, technical accuracy and cost-efficient technology to minimize the consequences of one of the most widespread chronic diseases; asthma.

Asia Connection

Spiromann is interested in exploring the opportunities of both manufacturing-facilities and partnerships with local healthcare actors throughout the growing region of East Asia.

GET IN TOUCH WITH

Spiromann